2,6-Dichloroisonicotinic acid

Enki Biopharmaceuticals (shanghai) Limited. is a cutting-edge pharmaceutical company committed to the comprehensive exploration, development, manufacturing, and commercialization of top-tier pharmaceutical products. The company established its state-of-the-art technology research and development center in Suzhou City, Jiangsu Province in 2016 and possesses production facilities located in Sichuan Province and Hunan Province. Enki Biopharma is propelled by technological research and development, with a primary focus on the R&D and production of high value-added and high-tech pharmaceutical intermediates/chiral compounds. The ultimate objective is to achieve industrialization through the creation of active pharmaceutical ingredients (APIs), while concurrently establishing core competencies in chiral synthesis, chemical/enzymatic catalysis, and clean production processes. The products primarily target premium foreign markets while simultaneously serving as intermediate support for domestic API production. Enki Biopharma embraces a market-oriented business philosophy, with innovation support and industrialization as its ultimate goals. It upholds the corporate spirit of focus, expertise, innovation, and win-win situations while remaining committed to the mission of creating value for customers, providing opportunities for employees, and promoting human health. Our utmost dedication lies in delivering high-quality products and premium services to our esteemed customers in order to achieve mutual success together. Simultaneously, we strive to foster employee development and promote social harmony.